At InjectCo MedSpa Fort Worth, medical weight loss begins with a health screen and lab work under physician supervision. If prescription GLP-1 treatment suits your health, a licensed prescriber working under Dr. Josh Allen, D.O., our Medical Director, decides which medicine and dose fit you. The program costs $425 a month.
We are inside Mattison Ave Suites in Chapel Hill Shopping Center, at Hulen Street and I-30. Many visits can happen by video, which helps if you live in Benbrook, Lake Worth or Weatherford.
COMPOUNDED MEDICATION IS NOT FDA-APPROVED
A prescriber may choose compounded semaglutide or tirzepatide for some plans. Compounded drugs are not FDA-approved: the FDA does not review them for safety, effectiveness or quality before they are marketed, and says they should be used only when an FDA-approved drug cannot meet a patient’s needs.
Before your first dose, you will know the exact product, whether it is compounded, which facility dispensed it and why it was chosen.
When someone tells us they are taking semaglutide or tirzepatide, the drug name is only the start of the conversation. We need to know exactly what was prescribed, where it came from, what the label says, and how the patient was told to measure or give it.
That matters even more with compounded medication, because concentrations and packaging are not always the same from one preparation to the next. We do not want anyone relying on an old screenshot, someone else’s instructions, or a syringe-unit number found online. Before the first dose, the medicine and the instructions should match the current prescription label.
At follow-up we also look at how you are tolerating treatment: nausea, hydration, bowel changes, appetite, whether you can eat and drink normally, and anything else that could change what the prescriber considers next. The goal is not to move you up a dose because the calendar says it is time. The goal is to make sure the treatment you actually received is the treatment the prescriber intended.
Prescribing decisions. Every prescription comes from a licensed prescriber working under Dr. Josh Allen, D.O., InjectCo’s Medical Director. That prescriber reads your history and labs, decides whether a medicine is appropriate, and approves any dose change. Dr. Allen is a Lake Erie College of Osteopathic Medicine graduate who did his emergency medicine residency with Texas A&M. See his NPI record (1982904033) or the Texas Medical Board lookup.
Check-ins. Jill, BSN, RN, and Cameron, BSN, RN, are our Fort Worth nurse injectors, and either may run your check-ins every two weeks. Neither nurse prescribes or changes a dose. Texas nursing licenses are listed on the Board of Nursing lookup.
FDA-approved semaglutide and tirzepatide products went through FDA review, and each comes with official prescribing information. Compounded versions, prepared by a pharmacy or outsourcing facility, are not FDA-approved or generic, and they are a different product from the approved drug even when the active ingredient shares its name. The FDA calls a seller’s claim that a compounded drug is the same as an approved one a red flag, and says compounded drugs “should only be used in patients whose medical needs cannot be met by an FDA-approved drug” (FDA).
When a Fort Worth prescription is compounded, a 503B outsourcing facility fills it. Registration means only that the FDA received the facility’s information, not that it makes FDA-approved drugs or meets manufacturing quality (CGMP) rules (FDA Q&A). Look up the facility on your label on the FDA’s registered outsourcing facilities list.
FDA status checked September 25, 2026: neither drug is on the FDA drug shortage list or the 503B bulks list, and both shortages were declared resolved by February 2025 (FDA). An April 30, 2026 FDA proposal to exclude both from that list closed for comments July 30, 2026, with no final decision published when we checked.
Semaglutide salt forms. Ask whether compounded semaglutide is made with semaglutide base. The FDA considers the sodium and acetate forms different active ingredients and knows of no lawful basis for compounding with them.
Compounded injections are not made at one standard strength. Two vials can both say semaglutide or tirzepatide and hold different amounts per milliliter, so the milligram dose, the milliliters drawn up and the “units” on a syringe are not interchangeable.
Dosing errors with compounded semaglutide have been reported to the FDA, some needing hospital care. Causes included mix-ups between milligrams, milliliters and units, oversized syringes, differing concentrations and professional calculation mistakes (FDA alert). By May 31, 2026 it had 990 adverse event reports involving compounded semaglutide and more than 730 involving compounded tirzepatide (FDA); a report alone does not prove the medicine caused the problem.
That is why this page lists no doses, unit conversions or schedules. Follow only the label on the product you received, and call us before you inject if anything does not match.
Took too much? Call Poison Help at 1-800-222-1222 or our clinic at (817) 285-5254. For severe or life-threatening symptoms, call 911.
Both are prescription weight loss medications, often called weight loss injections. Each mimics gut hormones (incretins) involved in appetite and blood sugar, which is why this care is sometimes called metabolic weight loss. They slow stomach emptying and turn down hunger.
Semaglutide is a GLP-1 receptor agonist. Tirzepatide is a dual GIP and GLP-1 receptor agonist, not simply another GLP-1. Both appear in the NIDDK guide to weight management medicines.
Looking for tirzepatide in Fort Worth? It is part of this program. For semaglutide-only questions, see semaglutide weight loss in Fort Worth.
No single answer on your health history picks the medicine. Your prescriber weighs these together:
Because the FDA says compounded GLP-1 drugs should only be used when an approved drug cannot meet a patient’s needs, it is fair to ask why a compounded option is recommended for you.
| Semaglutide label | Tirzepatide label | |
|---|---|---|
| How it works | GLP-1 receptor agonist | Dual GIP and GLP-1 receptor agonist |
| Approved uses (2026) | Chronic weight management; lowering major heart-event risk in adults with heart disease and obesity or overweight; MASH liver disease with fibrosis in adults | Chronic weight management in adults; moderate to severe obstructive sleep apnea in adults with obesity |
| Approved forms | Weekly injection or daily tablet | Weekly injection |
| Birth control pills | No switch instruction | Switch to a non-oral method, or add a barrier method, for 4 weeks after starting and after each dose increase |
| Other oral medicines | Consider extra monitoring for medicines that need close monitoring | Monitor medicines with a narrow therapeutic range, such as warfarin |
| Planning a pregnancy | Stop at least 2 months before | Stop when pregnancy is recognized |
From the current FDA labels for semaglutide (June 2026) and tirzepatide (August 2026). A compounded preparation has no FDA label of its own, and your prescriber makes the call. Do not change any medicine yourself because of this table.
These trials tested the manufacturers’ own medicine with lifestyle support, not compounded versions. Neither result is an InjectCo outcome or a forecast for you.
| STEP 1 | SURMOUNT-1 | |
|---|---|---|
| Medicine studied | Semaglutide 2.4 mg weekly | Tirzepatide 5, 10 or 15 mg weekly |
| Who took part | 1,961 adults with a BMI of 30 or more, or 27 or more with a weight-related condition; no diabetes | 2,539 adults with the same BMI criteria; no diabetes |
| Length | 68 weeks | 72 weeks |
| Average weight change | -14.9% (placebo -2.4%) | -15.0% at 5 mg, -19.5% at 10 mg, -20.9% at 15 mg (placebo -3.1%) |
| Journal | New England Journal of Medicine, 2021 | New England Journal of Medicine, 2022 |
| Important | Not an InjectCo compounded-medication outcome | Not an InjectCo compounded-medication outcome |
Our nurses never change or hold a dose themselves, and a planned increase can wait until side effects settle. Check-ins continue every two weeks while you are in the program.
Nausea leads the list of common side effects on the approved products, followed by diarrhea, vomiting, constipation and belly pain, mostly early on and after a dose increase. Severe or persistent symptoms are not a sign the treatment is working and need a clinician’s review. We explain risks from the approved semaglutide and tirzepatide labels; our semaglutide side effects guide covers how long they last.
Thyroid risk is judged from history. Both labels rule the medicines out for a personal or family history of medullary thyroid carcinoma or MEN 2. A routine thyroid blood test does not rule MTC out, and the labels call routine calcitonin tests or thyroid ultrasound of uncertain value for early detection.
Warnings your prescriber watches for (not automatic reasons you cannot take the medicine):
Labs are part of the Fort Worth program. They are completed before a first prescription, and their cost sits inside the $425 a month. The tests depend on your history, medicines and conditions, so ask which ones were ordered, why, and where the draw will happen. Results inform the overall plan alongside your history and symptoms. No single lab value calculates your dose, and no routine lab test clears the thyroid cancer contraindication.
The FDA-approved weight management labels cover adults with obesity, and adults with overweight plus a weight-related condition. In the pivotal trials that meant a BMI of at least 30, or at least 27 with a condition. Meeting that number means you may meet one commonly used criterion, not that you qualify. Dr. Allen oversees how our program applies these criteria.
BMI is a screening measure; the CDC notes it does not directly measure body fat.
Weight regain can happen after the medicine stops. In the STEP 1 extension, 327 adults were followed for a year after semaglutide 2.4 mg and lifestyle support ended, and on average put back roughly two-thirds of their earlier loss (Diabetes, Obesity and Metabolism, 2022). It did not study tirzepatide or compounded products.
Obesity care is usually planned for the long term. The end of a prepaid program is a billing date, not a medical decision; whether to continue or stop is decided with your prescriber. See our guide to avoiding weight gain after stopping semaglutide.
This is an illustration, not a forecast. 20% sits near the 20.9% average for tirzepatide 15 mg in SURMOUNT-1. Semaglutide 2.4 mg averaged 14.9% in STEP 1. Both trials used brand-made medicine in selected adults, so these numbers cannot predict your own result or the result of a compounded medicine.
The Fort Worth program costs $425 a month, covering your nurse consultation, program labs, semaglutide or tirzepatide if prescribed, check-ins twice a month and a dose review each month. The $1,800 option pays for a 6 to 8 month program that includes the same items. Paid monthly, 6 months would total $2,550 and 8 months $3,400.
Before paying, ask for the written terms: how the $1,800 is billed, how long your program runs, and what happens if you cancel or your prescriber stops treatment for a medical reason. We do not bill insurance; HSA and FSA funds can often go toward eligible costs.
Approved patients can begin treatment the same day and pay over time instead of all at once.
How it works: apply online with CareCredit or Cherry in a few minutes, get a decision on the spot, then bring your approval to your appointment. Our team can help you compare options during your consultation and apply on the day if you prefer.
Terms and rates are set by the financing provider. Your nurse will walk you through your total cost, including any financing fee, before anything is booked.
Actual InjectCo patients, treated across our Texas clinics and shared with written consent. Individual results vary. These are not Fort Worth-only results.
Swipe or use the arrows to see more photos.
Clinic-wide Google reviews: InjectCo MedSpa Fort Worth holds a 4.9 rating on Google from 100+ reviews. These quotes cover all services, not weight loss, and appear as written.
See every review on the InjectCo MedSpa Fort Worth Google Business Profile.
InjectCo MedSpa Fort Worth is in Suite 152 of Mattison Ave Suites, 4701 West Fwy, in Chapel Hill Shopping Center at the southwest corner of Hulen Street and I-30. Central Market and Mi Cocina share the center, which has surface parking, so a clinic pickup or check-in can fit around a grocery run.
From downtown, Arlington or North Richland Hills, take I-30 west toward Hulen Street. From Weatherford, come east on I-30. From Lake Worth, take I-820 to I-30 east.
8:00 AM to 8:00 PM, Monday through Sunday
$425 a month, or $1,800 for a 6 to 8 month program with the same inclusions. Ask for the written billing and cancellation terms before you pay.
Your nurse consultation, program labs, semaglutide or tirzepatide once prescribed, check-ins every two weeks with Jill, BSN, RN, or Cameron, BSN, RN, and a monthly dose review.
A BMI of 30 or more, or 27 or more with a weight-related condition, is one common criterion. Your history, labs and medicines also matter, and a licensed prescriber decides.
Your program is physician-supervised. A licensed prescriber working under Dr. Josh Allen, D.O., InjectCo’s Medical Director, makes every prescribing decision. Jill and Cameron run check-ins and do not prescribe.
Many visits can happen by video, including consultations, check-ins and monthly reviews. Lab work cannot, so ask where yours will be drawn.
Semaglutide is a GLP-1 receptor agonist; tirzepatide is a dual GIP and GLP-1 receptor agonist. Their labels also differ on birth control pills and pregnancy planning.
No. It may share an active ingredient name, but it is a different, unapproved product, and trial results for the approved drugs do not transfer to it. Our article on compounded vs brand-name semaglutide explains the difference.
Nausea is most common, then diarrhea, vomiting, constipation and belly pain, mostly early on and after a dose increase. Call us if they worsen or will not settle.
Anyone who has had medullary thyroid carcinoma or has a close relative who has, anyone with MEN 2, and anyone who had a serious allergic reaction to the drug. By clinic policy we also do not prescribe during pregnancy or enroll people with type 1 diabetes.
Weight loss treatment is not for use in pregnancy, and both labels say to stop once pregnancy is recognized. The semaglutide label also says to stop at least 2 months before a planned pregnancy. Tell your prescriber if you are pregnant, trying to conceive or breastfeeding.
They carry labeled risks, including pancreatitis, gallbladder problems and a boxed warning about thyroid tumors in rodents, which is why screening and check-ins come with every prescription. See our pages on semaglutide safety and tirzepatide safety.
Tell your surgeon and anesthesia team that you take one. The FDA labels warn about breathing in stomach contents under anesthesia or deep sedation but do not set a stop schedule, so your procedure team and prescriber decide. Do not skip or stop doses on your own.
The labs ordered before your first prescription are part of the $425 a month and vary by patient. No routine lab rules out the MTC or MEN 2 contraindication, which rests on personal and family history.
No one can promise a number. Brand-name trials averaged 14.9% for semaglutide over 68 weeks and 15.0% to 20.9% for tirzepatide over 72 weeks, depending on dose. These are not compounded-medication results.
Weight regain can happen; in the STEP 1 extension it averaged about two-thirds of the lost weight within a year. Plan any stop with your prescriber, and see our tips on avoiding weight gain after stopping semaglutide.
The label should name you, the medicine, the concentration if compounded, the dose and the facility. We do not give unit conversions online, because they depend on the exact product. If a refill looks different or a shipment arrives warm, call us before you inject.
No. InjectCo MedSpa Fort Worth is a clinic. If your prescriber chooses a compounded preparation, a 503B outsourcing facility prepares and dispenses it, and its name is on your label. You can look that facility up on the FDA’s registered outsourcing facilities list.
Follow the storage directions on your own label, because they can differ between products. The FDA advises against using an injectable GLP-1 that arrives warm or with inadequate cold packs, so call us before using a package like that.
We do not bill insurance. HSA and FSA funds may cover eligible costs; your plan administrator can confirm. For drug prices outside our program, see semaglutide cost without insurance.
Yes. Patients come from Lake Worth, North Richland Hills, Arlington, Benbrook and Weatherford for semaglutide or tirzepatide programs, and most check-ins can happen by video. The service-area list above shows typical drive times.
Send the form and our Fort Worth team will set up your screening at the clinic or by video. It asks for health details, so read our privacy policy first, or call (817) 285-5254.
A medical evaluation and a prescription come before either medicine. Compounded products are not FDA-approved (FDA). Label contraindications: MTC in you or a close relative, MEN 2, or a prior serious allergic reaction to the drug. Weight loss treatment is not for use in pregnancy.
Full prescribing information: semaglutide and tirzepatide.
Think you are having a reaction? Phone our Fort Worth team at (817) 285-5254 (8:00 AM to 8:00 PM, seven days). For severe or life-threatening symptoms, such as severe lasting stomach pain, being unable to hold down liquids, passing out, or a swollen face, lips or throat, call 911 or go to an emergency room. Report side effects to the FDA on MedWatch.
Sources. STEP 1, NEJM 2021 (PubMed 33567185, DOI) · SURMOUNT-1, NEJM 2022 (PubMed 35658024, DOI) · STEP 1 extension, Diabetes, Obesity and Metabolism 2022 (PubMed 35441470, DOI) · FDA on unapproved GLP-1 products · FDA compounding rules.
FDA status checked September 25, 2026 · Pricing confirmed September 25, 2026 · Clinical content contributed by InjectCo’s clinical team · Last medically reviewed September 20, 2026.
Medically reviewed by Dr. Josh Allen, D.O., Medical Director, InjectCo MedSpa.
